RxDoctor Payments Data

Shannon Chakedis

Nurse Practitioner · Walnut Creek, CANPI 1134527690

Payments from drug & device makers

$6,313in general payments, 2019–2025

Across 270 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$504
  • Johnson & Johnson$468
  • Pfizer$406
  • Seagen Inc.$367
  • Daiichi Sankyo Inc.$348
  • Novartis$338
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$5,88993%
  • Education$4247%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,313 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$57,098
Medicare patients
305
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide33$737,058
CalquenceAcalabrutinib Maleate45$691,842
JakafiRuxolitinib Phosphate30$431,662
RevlimidLenalidomide23$404,633
CabometyxCabozantinib S-Malate15$371,193
XtandiEnzalutamide28$368,079
LenvimaLenvatinib Mesylate13$360,897
BrukinsaZanubrutinib38$353,678
ZejulaNiraparib Tosylate17$333,412
ImbruvicaIbrutinib19$325,856
Lenalidomide28$324,024
IbrancePalbociclib12$192,826
TagrissoOsimertinib Mesylate14$158,717
ZelborafVemurafenib12$138,849
XareltoRivaroxaban33$37,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$325$850,55959 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$296$737,05833 claims
Incyte CorporationJakafi$229$431,66230 claims
Bristol Myers SquibbRevlimid$295$404,63323 claims
Exelixis Inc.Cabometyx$126$371,19315 claims
Astellas Pharma US IncXtandi$149$368,07928 claims
Eisai Inc.Lenvima$36$360,89713 claims
Beigene USA, Inc.Brukinsa$21$353,67838 claims
GSKZejula$310$333,41217 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$104$325,85619 claims
PfizerIbrance, Eliquis$406$229,83758 claims
Johnson & JohnsonXarelto$468$37,34133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →